H.Res.1136 is a simple, nonbinding House resolution that “supports the goals and ideals of ‘Long COVID Awareness Month,’” acknowledges the scale and harms of long COVID, and calls for more medical research into its causes and treatments. It lists prevalence and economic-impact figures and flags disparate impacts across gender, race/ethnicity, transgender, and disability lines.
Because the resolution is symbolic rather than statutory, it does not change law or appropriate money. Its practical effect is political and programmatic: it signals congressional attention, provides language advocates can cite, and may increase pressure on federal agencies and appropriators to prioritize surveillance and research on long COVID.
At a Glance
What It Does
The resolution formally supports recognizing March as Long COVID Awareness Month, recites findings about prevalence, cost, and disparities, and expresses congressional support for more medical research into causes and treatments. It contains no funding authorization, regulatory directives, or new programmatic mandates.
Who It Affects
Primary audiences are long COVID patients and advocacy groups, federal public-health research actors (for example, NIH and CDC), and congressional committees that oversee health research and spending—chiefly Energy and Commerce. Employers, insurers, and state policymakers may see indirect pressure from the awareness effort.
Why It Matters
Symbolic resolutions shape agendas: this one consolidates congressional recognition of long COVID as a major post-pandemic health issue, elevates estimated economic harms, and creates a reference point for hearings, agency priority-setting, and advocacy for appropriations or regulations.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
H.Res.1136 is a short, single-purpose resolution in the House of Representatives that does three things: it supports the goals and ideals of Long COVID Awareness Month (March), it recognizes the personal and economic harms associated with long COVID, and it expresses support for more medical research into causes and treatments. The bill opens with a set of “Whereas” clauses that summarize the issuing Member’s view of prevalence, lingering risk after infection, functional harms, projected economic costs, and demographic disparities.
Because the text is a resolution rather than a statute, it has no force to change federal programs or obligate funding. Instead, the resolution is a formal congressional statement of position.
That makes it a tool of agenda-setting: committees, agency officials, advocates, and the press can cite it to justify hearings, grant program adjustments, or appropriation requests—but none of those downstream actions are required by the resolution itself.The resolution’s explicit call for “more medical research on the causes of and treatments for long COVID” puts research—rather than direct service provision, disability benefits changes, or insurance mandates—at the center of the congressional response the sponsor envisions. The text also highlights disparities (women; Hispanic/Latine, Black, transgender, and disabled people) and a multi-trillion-dollar 5-year economic projection, which frames long COVID as both a health-equity issue and a macroeconomic problem.Practically, adoption of the resolution would give advocates a congressional-record citation to support requests for NIH and CDC action, influence appropriators and oversight committees to prioritize long-COVID work, and reinforce public-health messaging during March awareness activities.
It does not, however, define long COVID clinically, direct specific research priorities, or create mechanisms for coordination across agencies—issues that would need separate statutory or appropriations action.
The Five Things You Need to Know
The resolution was introduced by Representative Valerie Foushee on March 25, 2026 and referred to the House Committee on Energy and Commerce.
It formally supports recognizing March as “Long COVID Awareness Month” and uses “Whereas” findings to summarize prevalence, harms, and disparities.
The text cites a worldwide impact figure of over 400 million people and uses a $3.7 trillion 5-year U.S. economic-cost projection to frame urgency.
It explicitly “expresses support for more medical research on the causes of and treatments for long COVID” but contains no appropriation clause or authority to fund research.
As a House resolution (H.Res.), it is nonbinding—it creates no legal rights, regulatory duties, or new federal programs.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Evidence and framing: prevalence, harms, and disparities
The preamble collects the sponsor’s factual assertions: long COVID can affect multiple organs, persists for months or years, remains common even among vaccinated people and with newer variants, and becomes more likely with each additional COVID infection. It also highlights functional harms (fatigue, reduced ability to work), a global case count (over 400 million), a projected $3.7 trillion U.S. economic burden over five years, and disparate impacts on specific demographic groups. Practically, these recitals set the rhetorical frame for the resolution and provide quotable findings for hearings, briefings, and advocacy—though the recitals do not create evidentiary standards or bind agencies to those estimates.
Congress formally supports Long COVID Awareness Month
This clause is a short declarative endorsement: the House “supports the goals and ideals” of the awareness month. Mechanically, that endorsement is symbolic—its purpose is to register congressional recognition rather than to compel action. Still, the clause can be used by stakeholders as a formal statement of congressional concern that legitimizes public outreach campaigns and can be cited in communications with federal agencies or funders.
Recognition of the need for public awareness about living with long COVID
Clause (2) emphasizes bringing awareness to the day-to-day challenges faced by people with long COVID. From an operational perspective, it invites, but does not direct, federal and state public-health entities, grantmakers, and nonprofits to intensify outreach, educational programming, and stigma-reduction activities during March. Because the resolution lacks statutory teeth, the effectiveness of that invitation depends on voluntary action by agencies and third parties.
Expressed support for expanding medical research
The resolution’s final clause urges more medical research into causes and treatments. That language is intentionally broad: it does not specify scope (basic science, clinical trials, epidemiology, or health-services research), funding levels, or which agencies should lead. In practice, the clause will likely be interpreted by stakeholders as a cue to press NIH, CDC, FDA, and congressional appropriators for targeted research funding and coordinated research agendas—tasks that require subsequent legislative or budget actions.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- People living with long COVID: The resolution elevates public awareness and reduces stigma by putting long COVID on the congressional record, which can improve access to information, community support, and legitimacy for disability claims or employer accommodations.
- Patient and advocacy organizations: National and local advocacy groups gain a formal congressional reference to support awareness campaigns, fundraising, and lobbying for research dollars or policy changes.
- Medical and research communities: Researchers and academic centers can use the resolution as justification when seeking grant funding, convening stakeholder workshops, or proposing coordinated research programs.
- Public-health communicators and nonprofits: Entities focused on education and outreach get a clear, time-bound (March) opportunity to amplify messaging and recruit partners for awareness events.
Who Bears the Cost
- Federal research and public-health agencies (NIH, CDC): The resolution will likely increase pressure on these agencies to prioritize long COVID projects without providing additional appropriations, creating programmatic and prioritization burdens.
- Congressional appropriators and committees: Lawmakers may face increased constituent and advocacy pressure to allocate new funding for research and services, requiring trade-offs within constrained budgets.
- Employers and insurers: While not directly regulated by the resolution, employers and payers may confront greater demands for workplace accommodations and coverage of long-COVID treatments as awareness and advocacy expand.
- State health departments and service providers: States may receive more public requests for long-COVID surveillance, services, and outreach without corresponding federal funding, imposing operational costs.
Key Issues
The Core Tension
The central dilemma is symbolic recognition versus substantive action: the resolution signals congressional concern and encourages research and awareness, but without appropriations, definitions, or mandates it risks producing heightened expectations without the resources or mechanisms necessary to deliver meaningful change—especially for historically underserved groups the bill highlights.
The resolution walks a familiar line: it elevates a public-health problem without attaching resources or obligations. That design makes it effective as a signaling device but opens it to two practical critiques.
First, stakeholders may read the exhortation for “more medical research” as a promise of funding or policy change; the resolution contains no appropriation language or statutory direction to translate that exhortation into concrete programs. Second, the bill frames long COVID with specific prevalence and economic estimates; those numbers can be useful for advocacy but are subject to methodological debate and could be disputed by agencies or outside analysts, weakening the factual basis for subsequent policy decisions.
Implementation gaps are substantive. The resolution does not define clinical criteria for long COVID, prioritize research streams (basic science versus trials versus health-services research), or propose mechanisms for coordinating federal, state, and private research efforts.
It recognizes disparities but does not identify policy levers to address them (for example, targeted funding, data-collection strategies, or access-to-care provisions). These omissions leave open the question of how congressional attention will translate into measurable improvements in diagnosis, treatment, or economic relief for affected populations.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.